Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > RE: Next round of financing
View:
Post by SouthernTierTom on Mar 08, 2022 7:34pm

RE: Next round of financing

WHEN..and at what level?

Thoughts??
Comment by 99942Apophis on Mar 08, 2022 7:55pm
SouthernTierTom WHEN..and at what level? Thoughts?? Calculated estimates for next round of financing will probably occur near or close to late summer of 2023. However Southern Tier Tom you needn't worry as the share price will be between $75 to $80 at the time which will only create minimal dilution. Sleep well all is good.
Comment by robertshaw on Mar 09, 2022 7:19am
AGREE, He is Blowjobjoe's old and new workmates, always with agenda.
Comment by SouthernTierTom on Mar 09, 2022 7:45am
WOW!! .... this must be a very low cost operator.  It was my belief they had less than 3M CAD in the kitty and well... with losses and a costly FDA trial underway it would be very impressive it the next round of financing could be pusehed that far back.  I will watch closely and hope that these 2023 estimates do in fact play out as per the bullboard's direction.  I hope the ...more  
Comment by SouthernTierTom on Mar 09, 2022 9:07am
ACTUALLY "fellas" ... A LOT of "burn rates" have been loe simply because Covid 19 ( the ongoing pandemic ) has slowed recruitment in many ongoing trials and allowed for "burn rates" to be at unrealistic low levels. This fact has been expsoed at most FDA invloved bio stocks with ongoing trials...I'm not quite as "knowledgeable' as sum of you appear ...more  
Comment by floatinketucky on Mar 09, 2022 9:16am
That's why theralase is such a value. but its not just covid. they have support from other areas. And the safety and durability are key.
Comment by SouthernTierTom on Mar 09, 2022 9:47am
Thanks "fellas" ... some great discussion for an obvious "focussed group /program" ; - ) * IMPORTANT "fellss" .. The reduced costs, for most junior bios invoilved in FDA processes, is due to reduced recruitment ..NOTHING to do with what the companies are attempting to treat... ACTUALLY "fellas" ... A LOT of "burn rates" have been loe simply ...more  
Comment by SouthernTierTom on Mar 09, 2022 12:55pm
WOW!!! - Gerbels ... NO financing eh? Harkens back to the story of jack and the magic beanstock ; - ) A SIMPLE question should never deliver such TOXIC discussion.. Sumthin appears "a-foot here and may be even a "yard" ; - ) Thanks "fellas" ... some great discussion for an obvious "focussed group /program" ; - ) * IMPORTANT "fellas" .. The reduced ...more  
Comment by ScienceFirst on Mar 08, 2022 8:17pm
SiutherTierTom has always come here to play FUD.  Go check his posts history.  The guy is shorting TLT.
Comment by 99942Apophis on Mar 08, 2022 8:50pm
I know who and what he is ScienceFirst thanks for your concern. He knows very well there is no current need for financing he is only interested in injecting fear & doubt in shareholders so he can steal their shares knowing full well this Newsletter to be released will hold very important & solid information. 
Comment by SouthernTierTom on Mar 08, 2022 10:30pm
Sheesh fellas... it was a simple question and quite an astute one given the circumstances, the history and the nature of speculative, junior bio investing. The responses leave you looking as though a nerve was struck. Just a question guys... and a valid one at that. Imho of course!   Good luck to all!
Comment by ScienceFirst on Mar 08, 2022 11:21pm
STT ... You should have done your own due diligence instead of playing FUD.  You just showed your "hidden" agenda! Debunked.  Easily.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250